Lynn Kramer
Chief Clinical Officer, Deep Human Biology Learning (DHBL)
Eisai US•Westport, Connecticut, United States
View LinkedIn ProfileExecutive Overview
Lynn D. Kramer, M.D., FAAN, is Chief Clinical Officer, DHBL (Deep Human Biology Learning) at Eisai and a member of the Eisai Co., Ltd. Executive Committee. In these roles, he oversees the product creation cycle, including clinical introduction and regulatory approval of innovative projects for all Eisai products. Dr. Kramer, who has been with Eisai since 2007, started as the Executive Vice President of Global Clinical Research, and was soon promoted to the additional role of Chief Operating Officer of Eisai Medical Research. In early 2009, he was named President of the Scientific and Operational Clinical Support Core Function Unit (SOCS CFU) and President of the Neuroscience, Product Creation Unit. He was named Chief Clinical Officer and a member of the Executive Committee, Eisai Company, Ltd. in 2012. In these functions he has been responsible for all functions including regulatory, biostatistics, data management, medical writing, clinical functions and clinical pharmacology and modeling and simulations. During this time, he has overseen the development and regulatory approval of several new molecular entities. Earlier in his career, he held senior positions in drug development including serving as Vice President Clinical Research and Head of the Therapeutic Area Strategy Team at Novartis, and Vice President Clinical Research at the R.W. Johnson Pharmaceutical Research Institute. Prior to his industry career he was Co-PI of an National Institutes of Health (NIH) sponsored epilepsy-focused program project in Los Angeles, California. Dr. Kramer is a Fellow of the American Board of Psychiatry and Neurology (1987) and the Philadelphia College of Physicians (1987). He previously served as the industry representative on the Peripheral and Central Nervous System Drugs Advisory Committee of the Food and Drug Administration (FDA) and on the Board of Directors at American Society for Experimental Neuro Therapeutics (ASENT). He currently is a member of the Pharma R&D Leadership Forum. In 2022, he became the 12th recipient of the 2022 Epilepsy Foundation’s Lifetime Accelerator Award. Dr. Kramer received his M.D. from Hahnemann Medical College. He completed his internship in internal medicine at the University of California at Irvine, and his residency in neurology at the University of Virginia.
Career Timeline
- Eisai USCurrent2007–Present· 19 yrs 9 mos
- Chief Clinical Officer, Deep Human Biology LearningCurrent2007–Present
- President Neuroscience and General Medicine Product Creation UnitNov 2012–Jun 2025
- Apr 2013–Jun 2025· 12 yrs 2 mos
- Corporate OfficerApr 2013–Jun 2025
- Jun 2009–Jun 2025· 16 yrs
- President Neurosience Product Creation UnitJun 2009–Jun 2025
- May 2007–Jun 2009· 2 yrs 1 mo
- Executive Vice President and Chief Operating OfficerMay 2007–Jun 2009
Education
Resident Neurology
University of VirginiaIntern in Medicine
UC IrvineDoctor of Medicine - MD
Medicine
Hahnemann Medical CollegeBachelor of Arts - BA
Multi/Interdisciplinary Studies
Lycoming College